Young J A, Garretson F, Westlake D L, Illig W P, Vogl S E
Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma.
Cancer Invest. 1989;7(6):565-70. doi: 10.3109/07357908909017531.
Eighteen evaluable patients with previously untreated Stage III and IV ovarian carcinoma were treated with six cycles of intraperitoneal cisplatin with intravenous cyclophosphamide and doxorubicin. Significant chemotherapy-related toxicities were observed, including one patient with fatal neutropenia and sepsis, two patients with transient severe nephrotoxicity, one patient with severe autonomic and motor neuropathy, and one patient with generalized debility. One patient had Tenckhoff catheter-related peritonitis, but no other morbidity was associated with the peritoneal catheters. Three of eight patients with optimal tumor bulk and none of 10 patients with suboptimal tumor bulk achieved pathologic complete response. The overall estimated median survival is 22 months. This treatment approach is associated with formidable toxicity, and the contribution of intraperitoneal cisplatin to the treatment of newly diagnosed ovarian carcinoma patients must be evaluated in randomized trials.
18例先前未经治疗的Ⅲ期和Ⅳ期卵巢癌患者接受了六个周期的顺铂腹腔内注射联合环磷酰胺及阿霉素静脉注射治疗。观察到了显著的化疗相关毒性，包括1例死于中性粒细胞减少症和败血症的患者、2例出现短暂严重肾毒性的患者、1例出现严重自主神经和运动神经病变的患者以及1例全身虚弱的患者。1例患者发生了与Tenckhoff导管相关的腹膜炎，但没有其他发病情况与腹膜导管相关。8例肿瘤体积最佳的患者中有3例达到了病理完全缓解，而10例肿瘤体积欠佳的患者中无一例达到病理完全缓解。总体估计中位生存期为22个月。这种治疗方法伴有严重毒性，顺铂腹腔内注射对新诊断卵巢癌患者治疗的贡献必须在随机试验中进行评估。
